Merck & Company (MRK) earnings
In the quarter ended June 2026, Merck & Company had revenue of $16.6B, up 5.1% on a year earlier, and diluted EPS of -0.54.
On August 4, 2026 it reported EPS of -0.13 against an estimate of -0.26 (beat).
The next report is expected on Thursday, October 29, 2026 before the market opens, with EPS expected around 2.14.
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Next | Thu Oct 29, 2026 | Before open | 2.14 | — |
| Last | Tue Aug 4, 2026 | Before open | -0.26 | -0.13 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from Merck & Company's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $16.6B | +5.1% | -0.54 | -130.7% | — | 2026-08-07 |
| Mar 31, 2026 | $16.3B | +4.9% | -1.72 | -185.6% | — | 2026-05-04 |
| Dec 31, 2025 | $16.4B | +5.0% | — | — | — | 2026-02-24 |
| Sep 30, 2025 | $17.3B | +3.7% | 2.32 | +87.1% | — | 2025-11-05 |
| Jun 30, 2025 | $15.8B | -1.9% | 1.76 | -17.8% | — | 2025-08-05 |
| Mar 31, 2025 | $15.5B | -1.6% | 2.01 | +7.5% | — | 2025-05-02 |
| Dec 31, 2024 | $15.6B | +6.8% | — | — | — | 2025-02-25 |
| Sep 30, 2024 | $16.7B | +4.4% | 1.24 | -33.3% | — | 2024-11-06 |
| Jun 30, 2024 | $16.1B | +7.2% | 2.14 | — | — | 2024-08-05 |
| Mar 31, 2024 | $15.8B | +8.9% | 1.87 | +68.5% | — | 2024-05-03 |
| Dec 31, 2023 | $14.6B | +5.8% | — | — | — | 2024-02-26 |
| Sep 30, 2023 | $16.0B | +6.7% | 1.86 | +45.3% | — | 2023-11-03 |
Questions
When does Merck & Company report earnings?
Merck & Company's next earnings report is expected on October 29, 2026 before the market opens.
How did Merck & Company do last quarter?
In the quarter ended June 2026, Merck & Company had revenue of $16.6B, up 5.1% on a year earlier, and diluted EPS of -0.54.
From Merck & Company's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.